{
  "id": "5c56033607647bbc4b00000c",
  "type": "yesno",
  "question": "Is Tisagenlecleucel effective for B-Cell Lymphoma?",
  "ideal_answer": "Yes,  CD19-targeting CAR T-cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large B-cell lymphoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29247018",
    "http://www.ncbi.nlm.nih.gov/pubmed/29385370",
    "http://www.ncbi.nlm.nih.gov/pubmed/30213399",
    "http://www.ncbi.nlm.nih.gov/pubmed/30111196",
    "http://www.ncbi.nlm.nih.gov/pubmed/30501490",
    "http://www.ncbi.nlm.nih.gov/pubmed/29914976",
    "http://www.ncbi.nlm.nih.gov/pubmed/30309857",
    "http://www.ncbi.nlm.nih.gov/pubmed/29451276",
    "http://www.ncbi.nlm.nih.gov/pubmed/29499750",
    "http://www.ncbi.nlm.nih.gov/pubmed/30190371"
  ],
  "snippets": [
    {
      "text": "The phase II JULIET trial suggests that the CD19-targeting CAR T-cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large B-cell lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29247018",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29385370",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29385370",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29385370",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29914976",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29914976",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29914976",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.<br><b>METHODS</b>: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30501490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found.<br><b>CONCLUSIONS</b>: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30501490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This was a milestone in tumor immunology on account of the significant antitumor effect of tisagenlecleucel for the treatment of relapsed/refractory B-ALL patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On August 30, 2017, the U.S. Food and Drug Administration (FDA) approved Novartis' tisagenlecleucel (CTL-019, Kymriah), which is a synthetic bioimmune product of anti-CD19 chimeric antigen receptor (CAR) T cells, for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Within the last one year, two anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the United States Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma after at least two lines of systemic therapy based on multicenter single-arm phase two clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213399",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On August 30, 2017, the U.S. Food and Drug Administration approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30309857",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30111196",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Background: Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR19) T-cell therapy approved for the treatment of children and young adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30190371",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}